In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, talks about the factors that are impacting the ...

So far, the only high-concentration Humira biosimilar with FDA approval is Samsung Bioepis and Organon's Hadlima HC, which is expected to launch in the summer. Additionally, all of the FDA ...

INCHEON, Korea & JERSEY CITY, N.J., May 27, 2025--Organon and Samsung Bioepis' HADLIMA granted FDA interchangeability designation approval for all high- and-low concentration presentations.

Most are, however, working to get interchangeable status for their biosimilars, and three of them – Organon/Samsung Bioepis’ Hadlima, Sandoz’ Hyrimoz, and Celltrion’s Yuflyma – already ...

In the first part of her Pharma Commerce video interview, LeAnn Boyd, Liviniti’s founder and CEO, outlines the most critical root causes of rising healthcare and drug costs that the MFN executive ...